GeoVax Labs, Inc. 8-K

What Happened

• GeoVax Labs, Inc. announced a private placement under a Purchase Agreement dated May 18, 2026 that closed on May 19, 2026. The Company sold pre‑funded warrants and common warrants at an offering price of $1.4799 per pre‑funded warrant plus accompanying common warrants, generating approximately $2.7 million in net proceeds after placement agent fees and offering expenses.
• The offering included pre‑funded warrants exercisable for up to 2,027,027 shares of common stock (exercise price $0.0001 per share) and common warrants to purchase up to 4,054,054 shares (composed of 2,027,027 Series A warrants and 2,027,027 Series B warrants). Series A warrants expire five years after issuance; Series B warrants expire 18 months after issuance. Securities were issued in an unregistered transaction under Section 4(a)(2) and Rule 506 of Regulation D.

Key Details

• Net proceeds to GeoVax after fees/expenses: approximately $2.7 million.
• Pre‑funded warrant shares available: 2,027,027; Common Warrant Shares available: 4,054,054 (total potential new shares = 6,081,081).
• Exercise prices and expirations: Pre‑funded warrants $0.0001 (immediately exercisable); Common warrants $1.48 (Series A — 5 years; Series B — 18 months).
• Placement agent: A.G.P./Alliance Global Partners; cash fee = 7.0% of gross proceeds plus reimbursement of certain expenses (up to $70,000 accountable; up to $20,000 non‑accountable) and a 6‑month tail fee.
• Company agreed to customary closing conditions and limited issuance/registration actions for 60 days (and certain restrictions on variable‑rate transactions for 180 days). Warrant ownership caps prevent holders from owning more than 4.99% (or 9.99% if elected) of outstanding shares post‑exercise.

Why It Matters

• The financing provides immediate working capital and general corporate funds (~$2.7M net) but also creates potential dilution: up to 6,081,081 new shares could be issued if all pre‑funded warrants are exercised and all common warrants are issued/exercised.
• If all common warrants are exercised at $1.48 per share, that would generate additional proceeds of roughly $6.0 million to the company (in addition to the current net proceeds), though exercise is not guaranteed.
• Terms (immediate exercisability of pre‑funded warrants, exercise prices, expirations, and ownership caps), the placement agent fee, and the resale/registration exemptions are material details retail investors should note when evaluating share count dilution, potential future capital, and short‑term trading/resale restrictions.